SBIR Phase I: Bioactive, High-Strength Contrast Agents for Orthopedic and Bone Applications

这个小企业创新研究（SBIR）第一阶段项目旨在开发用于骨科和骨植入应用的生物活性、高强度造影剂。临床明显需要改良造影剂，以增加骨空隙填充物的强度、韧性和耐磨性，提高其生物相容性，促进骨/填充物界面健康骨生长的能力。这项创新解决了目前的缺点，旨在生产提高机械性能、疲劳寿命、磨损和与活骨生物相容性的造影剂。该项目的更广泛的影响/商业潜力是提高全关节置换术的成功率，增加种植体的使用寿命，减少翻修手术的发生率。包括髋关节和膝关节置换术（以及其他使用骨空隙填充物的手术）在内的手术在世界范围内迅速增加，并且在年轻患者人群中进行这些手术的趋势，他们更有可能需要置换手术，预示着未来几十年其发病率将大幅增加。

This Small Business Innovation Research (SBIR) Phase I project seeks to develop bioactive, high-strength contrast agents for use in orthopedic and bone implant applications. There is a clear clinical need for improved contrast agents that increase the strength, toughness and abrasion wear of bone-void fillers, improve its biocompatibility and ability to promote the growth of healthy bone at the bone/filler interface. The innovation addresses the current shortcomings and aims to produce contrast agents that improve the mechanical properties, fatigue life, wear abrasion, and bio-compatibility with living bone. The broader impact/commercial potential of this project is to increase the success rate of total joint replacement surgeries, increase the implant lifetime and reduce the rates of revision surgeries. Surgeries involving hip and knee replacements (and other surgeries utilizing bone-void fillers) are rapidly increasing world-wide, and the trend toward performing these surgeries on a younger patient population, who will more likely require replacement surgeries, portends a massive increase in their incidence in the coming decades.